Veradermics, Incorporated
MANE
$103.90
-$4.23-3.91%
NYSE
| 12/31/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -285.99% | ||||
| Total Depreciation and Amortization | -- | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -30.74% | ||||
| Change in Net Operating Assets | -408.18% | ||||
| Cash from Operations | -550.55% | ||||
| Capital Expenditure | -- | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -- | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -- | ||||
| Issuance of Preferred Stock | 184.39% | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -54.42% | ||||
| Cash from Financing | 197.21% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -65.49% | ||||